Gene and Cell Therapies Targeting CNS Disorders Market
完整報告名稱與涵蓋範圍
Gene and Cell Therapies Targeting CNS Disorders Market Size, Share & Trends Analysis Report By Products (Gene Therapy and Cell Therapy), By Indications, Region And Segment Forecasts, 2025-2034
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide Gene and Cell Therapies Targeting CNS Disorders Market is forecasted to register a CAGR of 30.5%.
Gene and Cell Therapies Targeting CNS Disorders encompasses key industry insights & findings from the report:
The growing incidence of central nervous system (cns) illnesses and the expanding need for efficient treatments are anticipated to propel the market. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is propelled by expanding appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, propelled by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene and Cell Therapies Targeting CNS Disorders Market Snapshot
Chapter 4. Global Gene and Cell Therapies Targeting CNS Disorders Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Gene Therapy
5.2.2. Cell Therapy
Chapter 6. Market Segmentation 3: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
6.2.1. Amyotrophic Lateral Sclerosis
6.2.2. Multiple sclerosis
6.2.3. Spinal Cord Injury
6.2.4. Alzehimer
6.2.5. Parkinson Disease
6.2.6. Huntington
6.2.7. Othe Indications
Chapter 7. Gene and Cell Therapies Targeting CNS Disorders Market Segmentation 4: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034
7.1.3. North America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.2.3. Europe Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.3.3. Asia Pacific Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.4.2. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.4.3. Latin America Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Products, 2021-2034
7.5.2. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) By Indications, 2021-2034
7.5.3. Middle East & Africa Gene and Cell Therapies Targeting CNS Disorders Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. BrainStorm Cell Therapeutics
8.2.3. Helixmith
8.2.4. Corestem
8.2.5. Q therapeutics
8.2.6. Helixmith
8.2.7. Rapa Therapeutics
8.2.8. BrainStorm Cell Therapeutics
8.2.9. Neuroplast
8.2.10. StemCyte
8.2.11. Ferrer Internacional
8.2.12. Neuralstem
8.2.13. Ferrer Internacional
8.2.14. Stemedica Cell Technologies
8.2.15. Libella Gene Therapeutics
8.2.16. Sangamo Therapeutics
8.2.17. Hoffmann-La Roche
8.2.18. Longeveron
8.2.19. Sio Gene Therapies
8.2.20. Prevail Therapeutics (Eli Lilly and Company)
8.2.21. NeuroGeneration
8.2.22. Brain Neurotherapy Bio (AskBio)
8.2.23. UniQure Biopharma
8.2.24. Neurogene Inc.
8.2.25. Passage Bio
8.2.26. AXOVANT SCIENCES GMBH
8.2.27. MeiraGTx Limited
8.2.28. Asklepios BioPharmaceutical (AskBio)
8.2.29. Biogen
8.2.30. Sarepta Therapeutics
8.2.31. REGENXBIO Inc.
8.2.32. Lysogene
8.2.33. Voyager Therapeutics
8.2.34. PTC Therapeutics
8.2.35. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們